COMMUNIQUÉS West-GlobeNewswire

-
Workhorse Health Introduces Innovative Mental Health Services for Ontario's Caregivers and Their Families
28/05/2024 -
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma
28/05/2024 -
CytoDyn to Host Webcast to Provide Company Update
28/05/2024 -
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
28/05/2024 -
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
28/05/2024 -
CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
28/05/2024 -
NewGenIvf Receives Nasdaq Notifications Regarding Market Value of Publicly Held Shares and Market Value of Listed Securities
28/05/2024 -
Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
28/05/2024 -
Evaxion Announces Business Update and First Quarter 2024 Financial Results
28/05/2024 -
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
28/05/2024 -
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
28/05/2024 -
Longeveron® to Attend BIO International Convention 2024
28/05/2024 -
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
28/05/2024 -
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
28/05/2024 -
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
28/05/2024 -
Spectral AI to Participate in Benzinga’s “AI Unleashed: Exploring the Possibilities” Virtual Event
28/05/2024 -
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
28/05/2024 -
Avalyn to Participate in Jefferies Global Healthcare Conference
28/05/2024 -
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)
28/05/2024
Pages